A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
← catalyst calendarNCT06747949 · readout in 1,210 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
844estimated
Sites
174
Countries
Argentina, Australia, Belgium +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-25 | actual | When the study began enrolling |
| Primary completion | 2029-12-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sjögren's Syndrome
Intervention
- Drug: Dazodalibep — also filed as AMG 611
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 152 weeks
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed